976 reports of this reaction
3.9% of all BIMEKIZUMAB reports
#5 most reported adverse reaction
HIDRADENITIS is the #5 most commonly reported adverse reaction for BIMEKIZUMAB, manufactured by UCB, Inc.. There are 976 FDA adverse event reports linking BIMEKIZUMAB to HIDRADENITIS. This represents approximately 3.9% of all 25,281 adverse event reports for this drug.
Patients taking BIMEKIZUMAB who experience hidradenitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HIDRADENITIS is moderately reported among BIMEKIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to hidradenitis, the following adverse reactions have been reported for BIMEKIZUMAB:
HIDRADENITIS has been reported as an adverse event in 976 FDA reports for BIMEKIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HIDRADENITIS accounts for approximately 3.9% of all adverse event reports for BIMEKIZUMAB, making it a notable side effect.
If you experience hidradenitis while taking BIMEKIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.